Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Luis Ruilope
The presence of renal damage is associated with an increased risk of a future development of cardiovascular events and death. There is a continuous relation between cardiovascular risk and renal function. Chronic kidney disease and cardiovascular disease can then develop in parallel as a consequence of similar risk factors. This fact explains the need for an early integral approach for these patients in an attempt to control cardiovascular risk.
The presence of renal damage is associated with an increased risk of future development of cardiovascular (CV) events and death. The enhanced risk is already present when microalbuminuria is detected in the presence of a totally preserved glomerular filtration rate (GFR). Since then and until the development of end-stage renal disease (ESRD), CV risk rises continuously to attain a maximum level 20 to 30 times above that of the general population (1).
Four stages have been defined before the development of ESRD (stage 5) in the evolution of Chronic Kidney Disease (CKD) as defined in the Kidney Disease Outcomes Quality Initiative (K-DOQI)(2). They are based on the level of estimated glomerular filtration rate (eGFR), obtained using the MDRD formula (3), or of estimated creatinine clearance using the Cockroft-Gault formula (4), and on the presence of albuminuria either micro (30-300 mg/g of creatinine) or macro (> 300 mg/g). The presence of albuminuria is more frequent with diminished values of eGFR and their simultaneous finding is accompanied by an additive effect on risk prediction.
The relevance of CKD for the prediction of CV disease has been demonstrated in the general (5) and hypertensive populations (6), as well as in patients with established cardiac disease in particular coronary artery disease (7), post-MI patients (8), and heart failure (9). The level of renal function has also been shown to be a good predictor of outcome after coronary interventions (10) and cardiac catheterization (11). The development of CKD is associated with the presence of classical CV risk factors in particular age, arterial hypertension, and hyperlipidemia (12) and recently it has been shown to be associated with the presence of metabolic syndrome (13). - In hypertensive patients longitudinal data have shown that the progressive decay of eGFR from normal or mildly diminished levels to values below 60 ml/min/m2 is accompanied by a significant increase in CV events and death during that evolution (14). CKD and CV disease can then develop in parallel being the consequence of the activity of similar risk factors (15) and both contribute independently to increase the risk prediction (16). Once CKD has progressed and eGFR are below the figure of 60 ml/min/m2, other factors specifically dependent on the level of renal insufficiency appear and contribute to enhance the level of CV risk. These are the presence of changes in calcium/phosphate homeostasis and the ulterior development of secondary hyperparathyroidism (17) and anemia due to a diminished renal production of erythropoietin (18). - In patients presenting with heart failure, it has been shown that renal function is independently associated with a heightened risk for death, CV death and hospitalisation from heart failure in patients with both preserved and reduced left ventricular ejection fraction (9). Interestingly, in heart failure the finding of a diminished level of eGFR could be, not the consequence of established renal disease but a direct reflection of an impaired hemodynamic status related to the severity of the underlying cardiac disease causing a functional derangement in renal function (19). Data from the CHARM study have shown that eGFR and cardiac function had effects that were independent in terms of predicting the primary end-point of the study (9).
The factors explaining the increased risk of CV events and death in the presence of any manifestation of CKD are the presence of advanced atherosclerosis and very frequently hypertensive vascular disease. This fact contributes to explain the frequent association of renal insufficiency and established CV disease and explains the need for an early integral CV intervention in an attempt to control all the different CV risk factors usually present in these patients (20)(Table 1). It also must be stressed that patients with renal insufficiency are less likely to be prescribed efficacious therapies in particular when situations like heart failure or established coronary artery disease are present (21). The prescription of the adequate medications is accompanied by better survival rates across the full spectrum of renal function (21). Table 1. Therapeutic attitudes in patients with renal damage and high cardiovascular risk.
LIFE-STYLE CHANGES : Salt intake, body weight, and smokingSTRICT BLOOD PRESSURE CONTROL : Goal BP control <130/80 mmHg, (<125/75 mmHg if proteinuria>1g/d ).Combination therapy required in most casesBlockade of angiotensin II effects is requiredCONTROL OF ASSOCIATED RISK FACTORS :Lipids: Statins, fibratesInsulin resistance: Insulin sensitizers (metformin, glitazones)Platelet aggregation: Aspirins, others
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1- Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8-18. 2- Kidney Disease Outcome Quality Initiative K-DOQI clinical practice Guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 suppl 2): S1-S266. 3- Levey AS, Bosch J, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-470. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10075613&query_hl=7&itool=pubmed_docsum 4- Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1244564&query_hl=10&itool=pubmed_docsum 5- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Eng J Med 2004; 351: 1296-1305 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15569840&query_hl=13&itool=pubmed_docsum. 6- Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-225. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11158211&query_hl=16&itool=pubmed_DocSum 7- Mann JFH, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 134: 629-636. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11304102&query_hl=19&itool=pubmed_docsum 8- Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofeke S, Leinberger JD, Caliiff R, Pfeffer M. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Eng J Med 2004; 351: 1285-1295. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15385655&query_hl=21&itool=pubmed_docsum 9- Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJV, Yusuf S, Granger CB, Michelson EL, Östergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16461840&query_hl=23&itool=pubmed_docsum 10- Cooper WA, O´Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, Petersen R, Peterson ED. Impact of renal dysfunction on outcomes of coronary bypass surgery: results from the Society of Thoracic Surgeons´s National Adult Cardiac database. Circulation 2006; 113: 1063-1070. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16490821&query_hl=25&itool=pubmed_docsum 11- Hemmelgarn BR, Southern DA, Humphries KH, Culleton BF, Knudson ML, Ghali WA. Refined characterization of the association between kidney function and mortality in patients undergoing cardiac catheterization. Eur Heart J 2006; dol:10, 1093/euroheartj/eh1846. 12- Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14970063&query_hl=27&itool=pubmed_docsum 13- Sarafidis PA, Whaley-Connell, Sowers J, Bakris GL. Cardiometabolic syndrome and chronic kidney disease: What is the link? JCMS 2006; 1: 58-65. 14- Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL, Ruilope LM. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616-1622. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15300154&query_hl=30&itool=pubmed_docsum 15- Chade AR, Brosh D, Higano ST, Lennon RJ, Lerman LO, Lerman A. Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease. Kidney Int 2006; 69: 266-271. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed 16- Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlóf B, Devereux RB, Kjeldsen SE Oikarinen L, Okin PM. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24: 775-781. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16531808&query_hl=33&itool=pubmed_docsum 17- Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-436. 18- Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized controlled trials. J Am Soc Nephrol 2004; 15: 3154-3165. 19- Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 1984; 69: 57-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=6689647&query_hl=41&itool=pubmed_docsum 20- Segura J, Garcia-Donaire JA, Praga M, Ruilope LM. Chronic Kidney Disease as a situation of high added risk in hypertensive patients. J Am Soc Nephrol 2006; suppl 2: S136-S140. 21- Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudson ML. The association among renal insufficiency, pharmacotherapy and outcomes in 6247 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587-1592. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15489090&query_hl=43&itool=pubmed_docsum
© 2016 European Society of Cardiology. All rights reserved